The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Courtney D. DiNardo, MD Anderson Cancer Center, Houston, US, about the use of venetoclax combinations in mutation subtypes of AML.

Introduction to a series of podcasts on the use of venetoclax combinations in mutation subtypes of AML

In this podcast, DiNardo gives an overview of the studies on venetoclax combinations presented at ASH 2020, especially venetoclax plus azacitidine, in mutation subtypes of AML.

DiNardo focuses on three specific subgroups: patients with IDH1/2 mutations; patients with FLT3 mutations; and patients with TP53 mutations. After talking about the promising results reported at ASH, DiNardo pointed out that unmet needs still exist, especially for patients with TP53 mutations.

Share: